Skip to main content
NCBI home page
Public Health Reports logoLink to Public Health Reports
. 1996 Jul-Aug;111(4):335–341.

Preventing perinatal transmission of HIV--costs and effectiveness of a recommended intervention.

R D Gorsky 1, P G Farnham 1, W L Straus 1, B Caldwell 1, D R Holtgrave 1, R J Simonds 1, M F Rogers 1, M E Guinan 1
PMCID: PMC1381878  PMID: 8711101

Abstract

OBJECTIVE. To calculate the national costs of reducing perinatal transmission of human immunodeficiency virus through counseling and voluntary testing of pregnant women and zidovudine treatment of infected women and their infants, as recommended by the Public Health Service, and to compare these costs with the savings from reducing the number of pediatric infections. METHOD. The authors analyzed the estimated costs of the intervention and the estimated cost savings from reducing the number of pediatric infections. The outcome measures are the number of infections prevented by the intervention and the net cost (cost of intervention minus the savings from a reduced number of pediatric HIV infections). The base model assumed that intervention participation and outcomes would resemble those found in the AIDS Clinical Trials Group Protocol 076. Assumptions were varied regarding maternal seroprevalence, participation by HIV-infected women, the proportion of infected women who accepted and completed the treatment, and the efficacy of zidovudine to illustrate the effect of these assumptions on infections prevented and net cost. RESULTS. Without the intervention, a perinatal HIV transmission rate of 25% would result in 1750 HIV-infected infants born annually in the United States, with lifetime medical-care costs estimated at $282 million. The cost of the intervention (counseling, testing, and zidovudine treatment) was estimated to be $ 67.6 million. In the base model, the intervention would prevent 656 pediatric HIV infections with a medical care cost saving of $105.6 million. The net cost saving of the intervention was $38.1 million. CONCLUSION. Voluntary HIV screening of pregnant women and ziovudine treatment for infected women and their infants resulted in cost savings under most of the assumptions used in this analysis. These results strongly support implementation of the Public Health Service recommendations for this intervention.

Full text

PDF
335

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arevalo J. A., Washington A. E. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA. 1988 Jan 15;259(3):365–369. [PubMed] [Google Scholar]
  2. Barbacci M., Repke J. T., Chaisson R. E. Routine prenatal screening for HIV infection. Lancet. 1991 Mar 23;337(8743):709–711. doi: 10.1016/0140-6736(91)90286-x. [DOI] [PubMed] [Google Scholar]
  3. Boyer P. J., Dillon M., Navaie M., Deveikis A., Keller M., O'Rourke S., Bryson Y. J. Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA. 1994 Jun 22;271(24):1925–1930. [PubMed] [Google Scholar]
  4. Brandeau M. L., Owens D. K., Sox C. H., Wachter R. M. Screening women of childbearing age for human immunodeficiency virus. A cost-benefit analysis. Arch Intern Med. 1992 Nov;152(11):2229–2237. [PubMed] [Google Scholar]
  5. Connor E. M., Sperling R. S., Gelber R., Kiselev P., Scott G., O'Sullivan M. J., VanDyke R., Bey M., Shearer W., Jacobson R. L. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3;331(18):1173–1180. doi: 10.1056/NEJM199411033311801. [DOI] [PubMed] [Google Scholar]
  6. Cozen W., Mascola L., Enguidanos R., Bauch S., Giles M., Paxton P., Henneman C., Finn M. Screening for HIV and hepatitis B virus in Los Angeles County prenatal clinics: a demonstration project. J Acquir Immune Defic Syndr. 1993 Jan;6(1):95–98. [PubMed] [Google Scholar]
  7. Davis S. F., Byers R. H., Jr, Lindegren M. L., Caldwell M. B., Karon J. M., Gwinn M. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA. 1995 Sep 27;274(12):952–955. [PubMed] [Google Scholar]
  8. Farnham P. G., Gorsky R. D., Holtgrave D. R., Jones W. K., Guinan M. E. Counseling and testing for HIV prevention: costs, effects, and cost-effectiveness of more rapid screening tests. Public Health Rep. 1996 Jan-Feb;111(1):44–54. [PMC free article] [PubMed] [Google Scholar]
  9. Hellinger F. J. The lifetime cost of treating a person with HIV. JAMA. 1993 Jul 28;270(4):474–478. [PubMed] [Google Scholar]
  10. Hsia D. C., Fleishman J. A., East J. A., Hellinger F. J. Pediatric human immunodeficiency virus infection. Recent evidence on the utilization and costs of health services. Arch Pediatr Adolesc Med. 1995 May;149(5):489–496. doi: 10.1001/archpedi.1995.02170180019003. [DOI] [PubMed] [Google Scholar]
  11. Lewis R., O'Brien J. M., Ray D. T., Sibai B. M. The impact of initiating a human immunodeficiency virus screening program in an urban obstetric population. Am J Obstet Gynecol. 1995 Oct;173(4):1329–1333. doi: 10.1016/0002-9378(95)91381-5. [DOI] [PubMed] [Google Scholar]
  12. Matheson P. B., Abrams E. J., Thomas P. A., Hernán M. A., Thea D. M., Lambert G., Krasinski K., Bamji M., Rogers M. F., Heagarty M. Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. The New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis. 1995 Aug;172(2):353–358. doi: 10.1093/infdis/172.2.353. [DOI] [PubMed] [Google Scholar]
  13. Rugg D. L., MacGowan R. J., Stark K. A., Swanson N. M. Evaluating the CDC program for HIV counseling and testing. Public Health Rep. 1991 Nov-Dec;106(6):708–713. [PMC free article] [PubMed] [Google Scholar]
  14. Tengs T. O., Adams M. E., Pliskin J. S., Safran D. G., Siegel J. E., Weinstein M. C., Graham J. D. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995 Jun;15(3):369–390. doi: 10.1111/j.1539-6924.1995.tb00330.x. [DOI] [PubMed] [Google Scholar]

Articles from Public Health Reports are provided here courtesy of SAGE Publications

RESOURCES